Who owns XFOR?
Institutional ownership of X4 Pharmaceuticals Inc. from Form 13F, Q2 2026
88 institutional managers reported holding X4 Pharmaceuticals Inc. (XFOR) in Form 13F filings for Q2 2026, with 102,095,830 shares worth $477M. The largest reported holder was Morgan Stanley. Managers that filed both quarters added a net 7,084,493 shares (+7.5%). 32 opened new positions and 26 sold out.
- Funds holding
- 88
- Value held
- $477M
- New / sold out
- 32 / 26
- Net shares, same filers
- +7.5%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of XFOR
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Morgan Stanley | $44.2M | 9.3% | 9,461,279 | Unchanged |
| FMR LLC | $38.9M | 8.2% | 8,321,657 | Added |
| Bain Capital Life Sciences Investors, LLC | $37.2M | 7.8% | 7,967,454 | Unchanged |
| Perceptive Advisors LLC | $37.0M | 7.8% | 7,933,491 | Added |
| Kalehua Capital Management LLC | $34.8M | 7.3% | 7,445,680 | Unchanged |
| Saturn V Capital Management LP | $32.6M | 6.8% | 6,973,343 | Added |
| Empery Asset Management, LP | $32.4M | 6.8% | 6,930,591 | Trimmed |
| Deep Track Capital, LP | $27.5M | 5.8% | 5,878,757 | Trimmed |
| BlackRock, Inc. | $25.9M | 5.4% | 5,554,906 | Added |
| Nantahala Capital Management, LLC | $22.9M | 4.8% | 4,898,936 | Added |
| Vanguard Capital Management LLC | $17.4M | 3.6% | 3,715,859 | Added |
| Rosalind Advisors, Inc. | $15.0M | 3.1% | 3,214,766 | Unchanged |
| Braidwell LP | $13.6M | 2.9% | 2,922,754 | Trimmed |
| Blackstone Inc. | $12.5M | 2.6% | 2,681,922 | Unchanged |
| Trails Edge Capital Partners, LP | $12.0M | 2.5% | 2,571,478 | Unchanged |
| BVF Inc | $10.4M | 2.2% | 2,233,742 | Unchanged |
| Geode Capital Management, LLC | $9.8M | 2.1% | 2,098,047 | Added |
| Venrock Adviser, LLC | $9.0M | 1.9% | 1,934,253 | Added |
| Samsara Biocapital, LLC | $6.5M | 1.4% | 1,395,587 | Trimmed |
| State Street Corp | $6.1M | 1.3% | 1,296,017 | Added |
| Woodline Partners LP | $4.7M | 1.0% | 1,001,095 | Unchanged |
| Goldman Sachs Group Inc | $4.3M | 0.9% | 916,536 | Added |
| Northern Trust Corp | $3.0M | 0.6% | 652,849 | Added |
| Vanguard Fiduciary Trust Co | $2.7M | 0.6% | 572,038 | Added |
| Vanguard Portfolio Management LLC | $2.5M | 0.5% | 542,128 | New |
Share of 13F holdings is each fund's shares as a share of the 102,095,830 XFOR shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- BlackRock, Inc. Added+$20.3M
- Nantahala Capital Management, LLC Added+$11.4M
- Venrock Adviser, LLC Added+$7.5M
- Perceptive Advisors LLC Added+$5.6M
- Geode Capital Management, LLC Added+$5.4M
- State Street Corp Added+$4.2M
- Vanguard Portfolio Management LLC New+$2.5M
- Saturn V Capital Management LP Added+$2.4M
- Northern Trust Corp Added+$2.2M
- Verdad Advisers, LP New+$1.6M
Biggest sellers in Q2 2026
- Empery Asset Management, LP Trimmed-$9.4M
- Stempoint Capital LP Sold out-$7.0M
- Millennium Management LLC Sold out-$5.0M
- Susquehanna International Group, LLP Trimmed-$3.9M
- Deep Track Capital, LP Trimmed-$2.2M
- Samsara Biocapital, LLC Trimmed-$2.0M
- Braidwell LP Trimmed-$1.6M
- Marshall Wace, LLP Sold out-$1.4M
- UBS Group AG Trimmed-$977K
- Qube Research & Technologies Ltd Sold out-$904K
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $73.8M and sold $38.8M; 25 added and 12 trimmed.
Schedule 13D and 13G filings on XFOR
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-07-30BlackRock, Inc. SCHEDULE 13G filed by BlackRock Inc.Schedule 13G
- 2026-02-12MORGAN STANLEY SCHEDULE 13G filed by X4 Pharmaceuticals Inc.Schedule 13G
- 2025-11-14Nantahala Capital Management, LLC SCHEDULE 13G filed by X4 Pharmaceuticals Inc.Schedule 13G
- 2025-11-07FMR LLC SCHEDULE 13G filed by X4 Pharmaceuticals Inc.Schedule 13G
- 2025-11-03PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by X4 Pharmaceuticals Inc.Schedule 13G
- 2025-10-21Empery Asset Management, LP SCHEDULE 13G filed by X4 Pharmaceuticals Inc.Schedule 13G
- 2025-08-20BIOTECHNOLOGY VALUE FUND L P SCHEDULE 13G filed by X4 Pharmaceuticals Inc.Schedule 13G
Questions about XFOR ownership
- Who owns XFOR stock?
- 88 institutional investment managers reported XFOR positions in their Form 13F filings for Q2 2026, holding 102,095,830 shares worth $477M in total. Morgan Stanley reported the largest position.
- Are funds buying or selling XFOR?
- In Q2 2026, 32 managers opened new XFOR positions, 25 added, 12 trimmed and 26 sold out. Managers that filed in both quarters added a net 7,084,493 shares.
- How current is this XFOR institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to XFOR by CUSIP. Options are left out. XFOR news and filings · XFOR insider trades · Top funds